The short answer
TB-500 is supplied lyophilised and is most stable dry, cold and dark. Its composition rules out the common chemical degradation routes, no disulfides, no methionine oxidation, no deamidation hotspot,leaving hydrolysis and, more practically, physical adsorption to container surfaces.
Key facts
- Supplied as
- White lyophilised powder
- Disulfide risk
- None (no cysteine)
- Oxidation risk
- Low (no methionine)
- Deamidation
- No asparagine
- Main chemical route
- Hydrolysis
- Main practical loss
- Adsorption to surfaces
- Freeze-thaw
- Avoid by aliquoting
Why the usual advice mostly does not apply
Most peptide storage guidance is written around cysteine and methionine, disulfide scrambling and thioether oxidation. TB-500 has neither, and no asparagine either, so deamidation at the classic hotspot is also absent. As a chemical entity it is unusually forgiving, and the standard emphasis on protecting from oxidation is largely beside the point here.
What actually degrades it
Hydrolysis of the peptide backbone, which water enables and which is why the lyophilised form is the stable one. Freeze-drying removes the participant in that reaction, and cold storage slows what remains. Seven residues means few bonds to hydrolyse, so even this is slow relative to a larger peptide.
Research material referenced
TB-500 5mg, third-party HPLC tested
The loss mechanism that matters more
Adsorption. A small, strongly charged peptide binds to glass and plastic, and at low working concentrations the fraction lost to the vial and pipette tips can be a substantial share of the material. This is a physical loss with no chemical signature. The peptide that remains is intact, there is simply less of it than the calculation assumed. Low-binding consumables and minimising transfers are the practical responses.
Reconstitution
Introduce diluent gently down the vial wall rather than onto the powder, and swirl rather than shake. Foaming indicates an air-liquid interface has been created, and peptides unfold at that interface before aggregating. TB-500 dissolves readily given its charge and hydrophilicity, so vigorous agitation is never necessary.
After reconstitution
Aliquot into single-use volumes. Repeated freeze-thaw cycling concentrates solutes at the advancing ice boundary and creates fresh interfaces each cycle. Damage that the absence of oxidation-prone residues does nothing to prevent. Chemical robustness is not the same as physical robustness.
A note if the material is the full protein
If a vial actually contains full-length thymosin beta-4 rather than the heptapeptide, this guidance is incomplete: the 43-residue protein has a different composition, including methionine, and correspondingly different vulnerabilities. Establishing which compound is present is a prerequisite to handling it correctly.
Frequently asked questions
Does TB-500 need protecting from light?
Less than most peptides. There is no methionine to oxidise and no aromatic residue to photodegrade. Dark storage remains sensible but the specific liability is absent.
Why might I recover less than expected?
Adsorption to glass and plastic. A small, highly charged peptide binds surfaces, and at low concentrations that loss is significant.
Does it need a reducing agent?
No. There is no cysteine in the sequence.
Continue researching
Peer-reviewed guides, comparators and matched reference materials.
Primary sources & clinical trials
Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.
- PubChemPubChem · TB-500 (CID 62707662)pubchem.ncbi.nlm.nih.gov
- PubMedStability of protein pharmaceuticals: an update. Pharm Res (PMID 20143256)pubmed.ncbi.nlm.nih.gov
- PubMedNail SL et al., Fundamentals of freeze-drying. Pharm Biotechnol 2002 (PMID 12189727)pubmed.ncbi.nlm.nih.gov
- PubMedGoldstein AL et al., Thymosin β4: a multi-functional regenerative peptide. Expert Opin Biol Ther 2012 (PMID 22074294)pubmed.ncbi.nlm.nih.gov
- PubMedShrivastava S et al., Thymosin beta4 and cardiac repair. Ann N Y Acad Sci 2010 (PMID 20536454)pubmed.ncbi.nlm.nih.gov
- PubMedSosne G et al., Thymosin beta 4 promotes corneal wound healing. Exp Eye Res 2002 (PMID 11950239)pubmed.ncbi.nlm.nih.gov
- TrialClinicalTrials.gov · Thymosin β4 (RGN-259) dry eye Phase 3 (NCT03925727)clinicaltrials.gov
- PubChemPubChem · Thymosin β4 (CID 16132341)pubchem.ncbi.nlm.nih.gov
- GuidelineGoogle: Creating helpful, reliable, people-first contentdevelopers.google.com
Browse the wider literature
Live database searches, not fixed citations. Results change as new work is indexed.
Written and reviewed by
William Heath · Editor, UK Peptides research library
William Heath edits the UK Peptides research library. He is responsible for what is published here: every article is sourced to primary literature, every purity or identity statement traces to a signed third-party certificate for a specific lot, and corrections are made in place with the review date updated. No scientific or medical credentials are claimed on this site; the evidence is carried by the cited sources and the certificates, not by the byline.
More TB-500 (Thymosin β4 fragment) articles
- TB-500 Half-Life and ClearanceA seven-residue peptide with no half-life extension carries no protection against renal filtration or peptidases. Why acetylation helps only at one end.
- Cell Migration: What the Studies ReportMigration requires continual actin remodelling, which gives a sequestering protein a plausible route to affect it. What the assays measure and what they do not.
- Angiogenesis: What the Literature ReportsNew vessel formation requires endothelial cells to migrate, which connects it to actin biology. What the models show and why the mechanism is less direct here.
- TB-500 Benefits: What Is Established and What Is NotActin sequestration, migration, angiogenesis, corneal and cardiac repair models. Sorted by how well each is established and which compound was actually used.
- TB-500 in the Published ResearchHow to search a literature where the compound name and the studied molecule frequently differ, and what the search strategy should be.